National STIQ Day 2022

Home - Archives for Martin Conway

National STIQ Day 2022

COVID-19 Testing        News        Contact Us

National STIQ Day 2022

14th January, National STIQ day was launched to get people thinking about the importance of sexual health and encourage everyone to get regular health checks.

More than 30 different bacteria, viruses and parasites are known to be transmitted through sexual contact. Eight of these pathogens are linked to the greatest incidence of sexually transmitted diseases (STI’s). STI’s are spread predominantly by sexual contact, including vaginal, anal and oral sex. Some STI’s can also be transmitted from mother-to-child during pregnancy, childbirth, and breastfeeding.

Any individual can catch an STI regardless of what age they are, their sexuality or how many sexual partners they have, as it only takes one sexual encounter to increase the risk of catching an infection. The importance of regular STI testing allows individuals to get peace of mind and take control of their sexual health as many infections don’t present symptoms and it’s advised that testing is required if individuals are concerned about their health, present symptoms or change sexual partner. Regular screening can aid in detecting an infection in the early stages and help to reduce the risk of such complications.

The increase in STI’s underline the need for urgent action which many reports have highlighted the need of ongoing inaction and development of strategies to improve sexual health. It has been widely noted by the CDC that over 20 million new STI’s are detected each year. (1) Public Health England also reported that 468,342 diagnoses of STIs had been reported in England in 2019 – a 5% increase from 2018 with a 26% increase in gonorrhoea infections, 10% increase in syphilis and 7% increase in the number of consultations at national sexual health services. It’s also widely noted that chlamydia testing, which is most common in young adults has declined by 13% since 2015 and 2% of all individuals tested had received a positive diagnosis. (2) (3)

Here at Randox, we offer solutions for clinical laboratories, point of care testing solutions and home STI testing kits for convenience and discretion. Randox provides the broadest STI testing menu on the market. Detecting 10 bacterial, viral, and protozoan infections, the STI test provides a comprehensive sexual health profile. The CE-marked STI Array provides the identification of co-infections, often in asymptomatic individuals and enable antibiotic stewardship.

The Randox test presents excellent precision, specificity, sensitivity and accuracy for STI diagnoses, which reduces the risk of false reporting and unnecessary confirmatory tests. The Randox simultaneous multiplex test means smaller sample volumes are required, enabling faster throughput and rapid patient diagnosis saving time and money for clinical and laboratories.

The Randox STI Multiplex test detects the following infections:

  • Chlamydia trachomatis (CT)
  • Neisseria gonorrhoeae (NG)
  • Trichomonas vaginalis (TV)
  • Mycoplasma genitalium (MG)
  • Treponema pallidum (Syphilis) (TP)
  • Herpes simplex virus 1 (HSV-1)
  • Herpes simplex virus 2 (HSV-2)
  • Haemophilus ducreyi (HD)
  • Mycoplasma hominis (MH)
  • Ureaplasma urealyticum (UU)

 

Does your laboratory or clinic carry out STI testing? Our molecular analyser, the Bosch Vivalytic and Evidence Investigator, powered by patented Biochip Array Technology, could be the diagnostic solution you need!

Solutions for the Laboratory

54 SAMPLES ● 1 TEST ● 10 INFECTIONS

 The Evidence Investigator is a compact semi-automated benchtop analyser ideal for medium throughput laboratories.

  • Sample Type: Swab or Urine
  • Sample Volume: 300 μl
  • Detection Method: Randox Biochip Technology (end-point PCR)
  • Time to Result: 5 hours 30 minutes

 

STI Testing at the Point of Care

1 SAMPLE ● 1 TEST ● 10 INFECTIONS

The Bosch Vivalytic enables sample to answer, cartridge based molecular diagnostics at

the point of care. Powered by Randox Biochip Technology.

  • Sample Type: Swab or Urine
  • Sample Volume: 300 μl
  • Detection Method: Randox Biochip Technology (end-point PCR)
  • Time to Result: 2 hours 30 minutes

 

For more information about our STI Arrays or Vivalytic email: marketing@randox.com

  1. https://www.cdc.gov/std/life-stages-populations/adolescents-youngadults.htm
  2. https://www.tht.org.uk/news/rise-stis-underlines-need-urgent-action
  3. Sexually transmitted infections (STIs) (who.int)

Related Products and Services

Evidence Investigator

Biosciences

ANTIBODY TEST

Vivalytic


Evaluation of Omicron Variant to Ensure Test Effectiveness

Randox Logo

   

7th December 2021

Evaluating Omicron and Other SARS-CoV-2 Variants to Ensure Test Effectiveness

SARS-CoV-2, like all viruses, evolves over time through mutations, as it spreads and replicates. Since the beginning of the COVID-19 pandemic, many variants of the SARS-CoV-2 virus, with different sets of mutations, have been observed worldwide. Most changes have little impact on the virus’ properties. However, some may cause increased transmissibility, severity of disease or the ability to evade the host immune response. Surveillance of genetic variations is therefore crucial to identify those variants which pose a higher risk to human health.

Variants may impact the performance of current diagnostic approaches. This is why Randox continuously review public genomic databases to assess whether any emerging mutations overlap with the assay design and monitor assay performance as part of post-market surveillance efforts to ensure the coronavirus assays continue to meet the highest quality standards.

In light of the emergence of the new variant of concern detected in South Africa, Omicron (B.1.1.529), Randox have analysed all publicly available sequences of the variant to predict any impact of defining mutations on assay designs.

As the COVID-19 assays from Randox Laboratories Ltd. are designed using a dual-target approach (ORf1ab, E gene) to reduce the impact of genetic variation in the SARS-CoV-2 genome, detection of SARS-CoV-2 is not predicted to be affected by the currently known variants.

Detection of SARS-CoV-2 using the Vivalytic rapid RT-PCR tests, targeting the E gene sequence are not affected by the identified mutations. Assay performance is not predicted to be impaired by the current known variants.

Randox Laboratories Ltd., in collaboration with leading technology manufacturer Bosch Healthcare Solutions, have developed a range of COVID-19 testing solutions, providing clear and concise results in a timely manner, directly at the point of care. Randox is a distributor for Vivalytic platform and cartridges.

For all enquiries regarding our COVID-19 assays performance , please contact marketing@randox.com

Randox in the media

Latest News

FAQs


Why are Neutralising Antibody tests important now?

COVID-19 Testing        News        Contact Us

27 October 2021- Why are Neutralising Antibody tests important now? 

Being prone to more frequent infections may mean that you have a weak immune system. With everything going on in the world, including COVID-19, this is important information that you need to know about yourself. As it stands, the pace of the vaccine booster rollout has slowed down and priority is given to people who are most vulnerable from developing a COVID-19 infection. This will offer those individuals the fullest protection against the virus this winter.  According to John Roberts, from the COVID-19 Actuaries Response Group, “At the start of the booster campaign, the health secretary Sajid Javid said: ‘We will protect the most vulnerable through the winter months’. But at the current rate it is going to be well through winter before we get through those first groups.”  This was stated on a BBC news article. (1)

This leads into the question that everybody is wondering…. Do we really need the booster vaccine? Infectious diseases expert, Professor Angus Dalgleish has commented during an interview on Good morning Britain that we should try another strategy.  A strategy where we should test people’s immunity first to see if they need the booster vaccine. He stated, “It should not be difficult for one test to see what your immune response to your last vaccine is or if you have had very bad COVID, have you got a good immune response and do you need the booster”. (2)

Laith Jamal Abu-Raddad, an infectious-disease epidemiologist at Weill Cornell Medicine—Qatar in Doha has also stated in an article from Nature that “Wasting resources on boosters for those who are already protected against severe disease does not really make too much sense,” (3)

The Randox SARS-CoV-2 Neutralising Antibody tests detects antibody levels post-vaccination to determine eligibility for a booster vaccination. These tests utilise patented biochip technology to detect neutralising antibodies to the Wuhan and Delta SARS-CoV-2 variants. There is a need for tests of this kind to provide an accurate estimate of immunity, monitor vaccine effectiveness and the frequency of post-vaccine breakthrough infections with variants of concern. Recent studies indicate that the delta variant is capable of re-infection even in fully vaccinated individuals and that a significant proportion of fully vaccinated individuals with breakthrough infections can transmit the virus to others.

The SARS-CoV-2 Neutralising Antibody tests are a quick and effective way to determine:

  • Longevity of immune response with response to post-vaccine infection, and variants of concern.
  • Population surveillance and testing of those at risk of sub-optimal vaccine response.
  • Measure antibody levels post-vaccination to determine eligibility for a booster vaccination.
  • Accurately detects antibodies that are capable of inhibiting virus replication and neutralizing the infectivity of the virus.

 

Want to know more?

For more information on SARS-CoV-2 Neutralising Antibody tests please visit the link below,

SARS-CoV-2 Neutralising Antibody Test | Randox Laboratories

Visit booking.randox.ie to book your COVID-19 antibody test today!

Alternatively contact us via email: marketing@randox.com

Sources linked-

  1. Covid: Is the pace of the vaccine booster rollout too slow? – BBC News
  2. ‘Don’t Panic’ Professors Questioned On The Rise In Covid Cases In England Sparking Concern | GMB – YouTube
  3. https://www.nature.com/articles/d41586-021-02158-6

Related COVID-19 Products and Services

CERTIFLY LATERAL FLOW

HOME TEST - PCR

ANTIBODY TEST

LABORATORY TOOLS


SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper

Randox Logo

30 June 2021

SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download

COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.

As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.

The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award

Discovery        News        Contact Us

Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award

 The Randox Discovery, an exciting and unique diagnostic analyser which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High Design Quality.

Red Dot, which has become established as one of the top profile product design awards has roots dating back as far as 1955 and determines the best products created each year. Recognised as one of the largest global product competitions for innovation excellence, this sought-after seal for quality design attracts submissions from over 50 countries, across 49 different categories including medical devices and technology.

 

Dr Stuart Jackson, Randox Project Design Engineer, commented;

“Randox are delighted to have achieved the Red Dot design award, the culmination of five years of development and coordination of engineering design teams spanning two continents. The Discovery is a particularly unique innovation capable of automating Randox Biochip molecular diagnostics assays, from sample lysis and end-point PCR to multiplexing detection, with accessibility and ease-of-use at the forefront of the design.”

Dolmen were briefed by the Randox team to develop a creative and dynamic way to showcase the cutting-edge inner workings of the Discovery. Essentially, to turn the magic of the machine into a piece of theatre; not just a tool, but the centre of attention, a focal point for the lab that has excellent usability and accessibility throughout. Dolmen and Randox collaborated closely to deliver a revolutionary instrument that, amongst its many abilities, is a COVID-19 diagnostic analyser that is the first of its kind.

Chris Murphy, CEO and Design Director, Dolmen Design and Innovation, commented;

“We are delighted that our collaboration with Randox has delivered another Red Dot design award for our team. Randox as a team truly value the power of design and how it can deliver better outcomes for end users. It is also wonderful to see our designs delivering positive change at the frontline of the COVID pandemic. This project was hugely collaborative, and we look forward to more collaborations in the future.”

What makes the Discovery special is its ability to conduct the full testing process, inclusive of sample preparation techniques such as extraction, purification, amplification and detection, in one highly intelligent, fully integrated space. The preparation of COVID-19 samples before testing was once lengthy and time-consuming, requiring a separate, sterilized laboratory for each stage, but can now be conducted on-board and by the fully automated Discovery platform, allowing a single operator to run multiple molecular tests simultaneously.

Combining almost 40 years of diagnostics into one platform, bringing multiple labs into one the COVID-19 diagnostic analyser is the first of its kind to combine sample preparation techniques and Biochip Technology.

Professor Dr. Peter Zec, Red Dot CEO, commented;

 “The winners of the Red Dot Award: Product Design 2021 were particularly impressive this year. The design of their products is excellent, in terms of both the aesthetic and the functionality. It’s not easy to prevail in such a strong field of competitors and to win over our jury. Consequently, I want to congratulate the laureates very sincerely on their success.”

For further information please email randoxpr@randox.com

 

Want to know more?

Contact us or visit our find out more about the Randox Discovery

Related Products

Randox Discovery

COVID 19 Product Overview

COVID 19 QPCR ASSAY

VIRAL RNA EXTRACTION KIT


World Health Day 2021

Randox Logo

   

7th April 2021

Building a fairer, healthier world

World Health Day is a global health awareness day celebrated every year on 7th April, under the sponsorship of the World Health Organisation (WHO) who sees it as an opportunity to draw worldwide attention to a subject of major importance to global health. Each year is related to a particular theme and this year’s focus is “building a fairer, healthier world”.

In view of the ongoing global COVID-19 pandemic where restrictions remain in place across most parts of the world, this time has highlighted that some people are able to live healthier lives and have better access to health services than others. COVID-19 has hit all countries hard, but its impact has been harshest on those communities which were already vulnerable, who are more exposed to the disease, less likely to have access to quality health care services and more likely to experience adverse consequences as a result of measures implemented to contain the pandemic, placing additional stress on healthcare systems across the world.

The COVID-19 pandemic has disrupted and even halted particular health services with most countries (90%) reporting that many routine and elective services have been suspended, while critical care – such as cancer screening and treatment and HIV therapy has seen high-risk interruptions (WHO, 2020).

the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.” (WHO, 2021).

Randox has adapted to the emergence of the COVID-19 pandemic by developing pioneering tests to diagnose COVID-19, offering a range of COVID-19 testing solutions using Randox’s patented Biochip Technology capable of conducting multiple tests simultaneously on a range of molecular testing platforms, with results available from the Vivalytic, Evidence Investigator and Randox Discovery.

With a game-changing global partnership formed between Randox Laboratories and Bosch Healthcare Solutions combining science and technology, successfully launching the Vivalytic – the all in one solution for molecular diagnostics, the Vivalytic has been designed against the challenges posed by climate change and to contribute towards sustainability. The Vivalytic cartridges are CO2 neutral – this means that emissions that are in our direct sphere of influence are neutralised – making a further contribution to climate protection.

Furthermore, Randox’s vision is to improve healthcare worldwide and to ensure physicians and the public have access to the latest advancements in clinical diagnostics to aid diagnosis, treatment, and management of patients. Randox offer a comprehensive biochip test menu to support and combat challenges facing global health on an everyday basis from testing for Chronic Lung Disease (CLD) to predicting Alzheimers Disease. View Randox’s full Biochip Technology Immunoassay test menu here.

Please contact marketing@randox.com for further information on any of the mentioned above.

Randox in the media

Latest News

FAQs


Approaching the Fundamental Impact of STIs Worldwide

Randox Logo

02 March 2021

The Global Economic Burden of STIs & The Impact of the COVID-19 Pandemic on Sexual Health Whitepaper Download 

Sexual Health encompasses; genito-urinary medicine, sexually transmitted infections (STIs), HIV, contraception, psychosexual medicine, abortion services, teenage pregnancy and sexual and reproductive health. It is delivered in various settings, providing care across specialised services as well as through primary and third sector organisations.

Sexual and reproductive health is a fundamental public health issue and is clearly recognised by the World Health Organisation (WHO). This whitepaper focuses on the profound impact of sexually transmitted infections (STIs) worldwide with WHO reporting that more than 1 million STIs are acquired every day (WHO, 2020).

The whitepaper discusses issues such as antimicrobial resistance, in particular gonorrhoea, and the challenges faced in a social and public concept due to the COVID-19 pandemic.

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Emerging SARS-CoV-2 variants: successful detection despite virus mutation

Randox Logo

02 February 2021

Test performance not affected by mutation found in new UK, South African and Brazilian variants.

The new SARS-CoV-2 variants that have been identified recently in the UK (known as 501Y.V1, VOC202012/01 or B.1.1.7 lineage), South Africa (known as 501Y.V2 or B.1.351 lineage) and Brazil (B.1.1.248 lineage), contain multiple mutations in the segment of the virus’ genome that codes for the spike protein.

Of particular interest is a double deletion at position 69-70 of the spike protein gene (69-70del), observed in the B1.1.7 variant, which has been found to affect the performance of some diagnostic PCR assays that use an S gene target (S gene dropout).

Detection of SARS-CoV-2 using the multiplex RT-qPCR assay from Randox Laboratories Ltd. is not affected by the identified mutations. This kit is a fast and highly sensitive multiplex diagnostic solution containing the necessary components to provide the detection of two genes (ORf I ab, E gene) to reduce the impact of genetic variation in the SARS-CoV-2 genome. The multiplex primer mix in this assay allows the amplification of specific gene sequences found within the genome of the pathogen, covering all variants. Therefore, the mutations in the B.I.I.7, B.I.351 and B.I.I.248 lineage variants do not affect the detection of SARS-CoV-2 by the PCR test.

Randox Laboratories Ltd. monitors SARS-CoV-2 variants in NCBI and GISAID databases and performs bioinformatics analysis regularly. Based on in silico analysis the performance of the test is not impacted by the mutations.

The Randox multiplex RT-qPCR diagnostic kit supports clinical and public health laboratories to quickly diagnose COVID-19 caused by SARS-CoV-2 infection, assisting the screening and isolation of individuals that require quarantine and immediate intervention.

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

   

21st December 2020

Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

Randox Laboratories is proud to announce the launch of its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both of the leading COVID-19 diagnostic antigens – Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP).

Maximum test sensitivity is ensured through simultaneous detection of both RBD-only and NP-only responders, making it superior to current commercially available COVID-19 IgG tests that are based on RBD or NP alone, from which false negative results can occur.

The Randox SARS-CoV-2 IgG (RBD & NP) Array provides clinicians with an opportunity to discriminate vaccinated individuals from those naturally infected by COVID-19.

Lynsey Adams, Randox Clinical Marketing Manager commented;

“When there is little or no access to molecular testing, serology tests provide a means to quickly triage suspected cases of COVID-19, enabling appropriate case management, and guiding public health measures, such as quarantine or self-isolation.

 “The new Randox SARS-CoV-2 IgG (RBD & NP) Array, provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID-19 pandemic progresses.”

 The Randox SARS-CoV-2 IgG (RBD & NP) Array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser delivering accurate results in just 1.5 hours.

Features of the new Randox SARS-CoV-2 IgG (RBD & NP) Array

  • Utilises established diagnostic antigen candidates – RBD and NP
  • IgG measurement confirms adaptive immune response to SARS-CoV-2
  • Clinical specificity of 99.5%
  • Clinical sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
  • Dual sample matrix: human serum/plasma.

Contact marketing@randox.com for further information on our latest SARS-CoV-2 array or click to find out more!

Randox in the media

Latest News

FAQs


Vivalytic’s rapid coronavirus test delivers results for positive samples in less than 30 minutes

   

18th December 2020

Cloud-based software update means a faster PCR test for SARS-CoV-2

We are happy to announce that due to improved software for the Vivalytic analysis device, the CE marked Vivalytic SARS-CoV-2 rapid coronavirus test, which uses polymerase chain reactions (PCR), now delivers its results even faster. By applying optimized evaluation strategies, the Vivalytic analysis device can detect a positive SARS-CoV-2 sample through its high viral load in less than 30 minutes, right where the sample is collected.

This modified product is part of a research and development project relating specifically to COVID-19, funded by the German Federal Ministry of Education and Research (BMBF) to the tune of 4.97 million euros. The project’s aim is to expand the options for detecting acute infections of the coronavirus, looking particularly at on-the-spot testing in which the sample is analyzed in a fully automatic PCR process, as this offers rapid yet reliable results.

  • Improved software for Vivalytic: turnaround time for positive SARS-CoV-2 samples reduced to under 30 minutes.
  • Update from the cloud: Vivalytic analysis devices are updated over the internet.

Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH said;

“In the fight to contain the coronavirus pandemic, speed is of the essence. With Vivalytic, we are delivering cutting-edge medical technology. Our IT and software expertise have helped to make the Bosch Corona test for positive samples even faster – all within a short period of time.”

The new update is available for the SARS-CoV-2 singleplex test and the SARS-CoV-2 pooled test. Updating the Vivalytic testing devices is simple and straightforward – all that is required is an internet connection to access the Bosch cloud platform Vivasuite. Developed in-house at Bosch, the Vivasuite cloud platform allows users to digitally manage and update all their Bosch Healthcare Solutions devices. This is also an advantage when Vivalytic devices are in use in the field. The platform meets the strictest security standards and data privacy is guaranteed at all times: for example, there is no remote access to Vivalytic devices, and no possibility of accessing patient data.

The turnaround time for samples negative for SARS-CoV-2 is still 39 minutes. PCR tests are considered the gold standard, and Bosch’s rapid coronavirus tests have a sensitivity of 98 percent and a specificity of 100 percent.

Contact marketing@randox.com for further information on the latest vivalytic software update for SARS-CoV-2 testing. 

Randox in the media

Latest News

FAQs


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.